The U.S. Food and Drug Administration on April 21, 2026, approved Merck’s Idvynso, a once-daily combination pill for HIV treatment that pairs two drug classes in a single tablet. The approval gives adults who are already virologically suppressed on antiretroviral therapy a new maintenance option, and it marks the first FDA clearance for islatravir, a drug whose development was delayed after safety concerns forced Merck to rethink its dosing strategy.
Idvynso combines doravirine (100 mg), a non-nucleoside reverse transcriptase inhibitor Merck already sells under the brand name Pifeltro, with islatravir (0.25 mg), a nucleoside reverse transcriptase translocation inhibitor that blocks HIV replication through a mechanism distinct from older drugs in its class. The combination is approved specifically as a switch therapy for adults whose current regimen has already brought their viral load to undetectable levels.
Why the islatravir dose matters
Islatravir was once considered one of the most promising molecules in HIV drug development, but higher doses tested in earlier trials caused unexpected drops in CD4 immune cells, the very cells HIV destroys. Merck paused multiple islatravir studies in 2021 and 2022 to investigate the problem, a setback that cast doubt on the drug’s future. The CD4 declines were documented in FDA review documents and in Merck’s own clinical hold disclosures during that period.
The 0.25 mg dose in Idvynso represents Merck’s solution: low enough to avoid the lymphocyte declines that derailed earlier programs, but potent enough to maintain antiviral activity when paired with doravirine. The FDA’s willingness to approve the combination suggests regulators were satisfied that this dose threads the needle between efficacy and safety, though long-term monitoring will be critical.
“Today’s approval provides an important new treatment option for adults living with HIV who have achieved viral suppression on their current antiretroviral regimen,” the FDA stated in its April 21, 2026, approval announcement.
The clinical evidence behind the approval
Three Phase 3 switch studies form the backbone of the approval. Trial 051 (NCT05631093) was an open-label study that enrolled virologically suppressed adults on various oral antiretroviral regimens and switched them to doravirine/islatravir. Trial 052 (NCT05630755) used a double-blind, active-controlled design and recruited participants who were already suppressed on bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy), one of the most widely prescribed HIV treatments in the U.S. A third study, MK-8591A-053 (NCT05705349), broadened the evidence base with additional suppressed adults.
All three trials measured the same primary endpoint: the proportion of participants with HIV-1 RNA below 50 copies per milliliter at Week 48. Merck presented results from these studies at the Conference on Retroviruses and Opportunistic Infections (CROI) earlier in 2026, reporting that the vast majority of participants who switched to Idvynso remained undetectable at 48 weeks, with virologic outcomes comparable to those who stayed on their prior regimens in the controlled trial.
Rates of confirmed virologic failure were low across all three studies, and investigators reported no clear signal of treatment-emergent resistance among the small number of participants who experienced viral rebound. Side effects were generally mild or moderate and consistent with the known tolerability profile of doravirine.
Subgroup analyses by age and sex
HIV clinical trials have historically enrolled disproportionately fewer women and older adults, leaving gaps in the evidence for drugs that millions of people take daily. Subgroup analyses presented at CROI addressed this directly. Abstract P-377, which examined Week 48 efficacy and safety outcomes by age across both switch trials, found that older adults maintained suppression at rates similar to younger participants. Abstract P-364, which stratified results by sex assigned at birth, reported consistent outcomes for women and men, with overlapping confidence intervals for both virologic success and adverse event rates. Both abstracts were presented at CROI 2026 and are indexed through the conference proceedings available via PubMed Central.
These findings carry the usual caveats of subgroup analyses: the numbers in each stratum are modest, and the studies were not powered to detect small differences between groups. Still, the consistency across age and sex is a positive signal, particularly for clinicians considering the switch for patients who are underrepresented in pivotal trial populations.
What the data do not yet show
The strongest published evidence covers 48 weeks. Whether Idvynso’s efficacy and safety hold beyond that window, particularly any delayed effects on lymphocyte counts at the 0.25 mg islatravir dose, remains an open question. Regulators will likely require extended follow-up from the Phase 3 program and postmarketing surveillance to confirm that the dose reduction continues to avoid the CD4 problems seen in earlier development.
Real-world adherence data do not yet exist. Clinical trials enroll motivated participants under structured conditions with frequent visits and adherence support. How Idvynso performs in routine care, where patients face insurance barriers, pharmacy access challenges, and competing health priorities, will only become clear after broader rollout.
No patient-reported outcome measures from the trials have been publicly disclosed. For many people living with HIV, the difference between regimens is not just viral load numbers but day-to-day tolerability: sleep quality, gastrointestinal symptoms, mood changes, and the psychological weight of pill burden. Without formal quality-of-life data, it is difficult to quantify whether Idvynso offers a meaningful improvement in lived experience over existing options.
Comparative efficacy against single-tablet regimens other than Biktarvy has not been directly tested. No head-to-head data exist against Dovato (dolutegravir/lamivudine) or Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), two other widely used options. Clinicians weighing a switch for stable patients will need to consider resistance barriers, drug interaction profiles, and individual comorbidities rather than relying on clear-cut superiority data that does not yet exist.
Where Idvynso fits in a changing treatment landscape
The approval arrives at a moment when HIV treatment is shifting toward simpler, less burdensome regimens. Long-acting injectable options like cabotegravir/rilpivirine (Cabenuva), administered every one or two months, have already changed the conversation about what maintenance therapy can look like. Two-drug oral regimens like Dovato have demonstrated that fewer active ingredients can be enough for many suppressed patients. Idvynso adds another entry to this simplification trend: two drugs, one pill, once a day.
Pricing and insurance coverage details have not been publicly disclosed as of late April 2026. For a drug positioned as a switch option rather than a first-line treatment, formulary placement and payer negotiations will heavily influence how quickly it reaches patients. Merck will need to demonstrate to insurers that Idvynso offers clinical or practical advantages that justify any premium over generic or established branded alternatives.
The U.S. Department of Health and Human Services HIV treatment guidelines, maintained by a panel of experts and updated regularly, had not yet incorporated Idvynso at the time of approval. Guideline updates typically follow FDA clearance by weeks to months as the panel reviews the full data package. Until those recommendations are published, prescribing decisions will rest on individual clinician judgment and the trial data now available through ClinicalTrials.gov and conference proceedings.
How the approval reshapes switch therapy decisions for suppressed patients
For the estimated 1.2 million people living with HIV in the United States, the practical significance of Idvynso will depend on factors the clinical trials were not designed to measure: cost, access, and whether the new option fits into the daily realities of long-term disease management. The 48-week data support a cautious but grounded optimism. Switching to Idvynso maintained viral suppression across the populations studied, the lower islatravir dose appears to have resolved earlier safety concerns, and subgroup analyses suggest the benefits are not limited to a narrow demographic.
But this is a maintenance therapy approval, not a breakthrough cure or a first-in-class revolution. Its value will be measured over years, not weeks, as longer-term data, real-world experience, and guideline integration fill in the gaps that 48-week switch trials cannot. For now, Idvynso gives clinicians and patients one more option in a treatment landscape that continues to expand, and for people who have lived with HIV through decades of evolving therapy, having choices has never been a small thing.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
